Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from SS Innovations International ( (SSII) ).
On January 6, 2026, SS Innovations announced it had completed development of five new 5-millimeter surgical instruments—spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps—for use with its SSi Mantra robotic platform, targeting procedures in pediatric, cardiac, and head and neck surgery and other operations involving smaller anatomical structures. By addressing large, underserved patient populations, particularly children in lower- and middle-income countries who currently lack access to timely, safe surgical care, these smaller instruments are intended to extend the reach of robotic surgery beyond predominantly adult use and enhance the SSi Mantra system’s competitiveness in high-precision specialties, potentially strengthening the company’s position in emerging markets and expanding its role in complex cardiac and head and neck procedures.
The most recent analyst rating on (SSII) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on SS Innovations International stock, see the SSII Stock Forecast page.
Spark’s Take on SSII Stock
According to Spark, TipRanks’ AI Analyst, SSII is a Neutral.
SS Innovations International shows strong growth potential with significant revenue increases and strategic initiatives such as FDA submissions and telesurgery advancements. However, profitability challenges and negative valuation metrics weigh heavily on the overall score. The technical analysis suggests a bearish trend, further impacting the stock’s attractiveness.
To see Spark’s full report on SSII stock, click here.
More about SS Innovations International
SS Innovations International, Inc. is a Nasdaq-listed developer of surgical robotic technologies focused on making robotic surgery more affordable and accessible globally. Its portfolio centers on the SSi Mantra surgical robotic system and the complementary SSi Mudra suite of instruments, designed for multi-specialty procedures including cardiac surgery. Headquartered in India with American corporate status, the company is expanding its international footprint, with 168 SSi Mantra systems installed as of December 31, 2025 across 153 hospitals in India and nine other countries, supporting more than 7,800 procedures, including over 120 telesurgeries and more than 400 cardiac operations.
Average Trading Volume: 101,705
Technical Sentiment Signal: Sell
Current Market Cap: $1.05B
For a thorough assessment of SSII stock, go to TipRanks’ Stock Analysis page.